NK105, a paclitaxel-incorporating micellar nanoparticle formulation, can extend in vivo antitumour activity and reduce the neurotoxicity of paclitaxel
Open accessThe DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index.
Abstract
Paclitaxel (PTX) is one of the most effective anticancer agents. In clinical practice, however, high incidences of adverse reactions of the drug, for example, neurotoxicity, myelosuppression, and allergic reactions, have been reported. NK105, a micellar nanoparticle formulation, was developed to overcome these problems and to enhance the antitumour activity of PTX. Via the self-association process, PTX was incorporated into the inner core of the micelle system by physical entrapment through hydrophobic interactions between the drug and the well-designed block copolymers for PTX. NK105 was compared with free PTX with respect to their in vitro cytotoxicity, in vivo antitumour activity, pharmacokinetics, pharmacodynamics, and neurotoxicity. Consequently, the plasma area under the curve (AUC) values were approximately 90-fold higher for NK105 than for free PTX because the leakage of PTX from normal blood vessels was minimal and its capture by the reticuloendothelial system minimised. Thus, the tumour AUC value was 25-fold higher for NK105 than for free PTX. NK105 showed significantly potent antitumour activity on a human colorectal cancer cell line HT-29 xenograft as compared with PTX (P<0.001) because the enhanced accumulation of the drug in the tumour has occurred, probably followed by its effective and sustained release from micellar nanoparticles. Neurotoxicity was significantly weaker with NK105 than with free PTX. The neurotoxicity of PTX was attenuated by NK105, which was demonstrated by both histopathological (P<0.001) and physiological (P<0.05) methods for the first time. The present study suggests that NK105 warrants a clinical trial for patients with metastatic solid tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The size of polymeric micelles currently in clinical trials are less than 100 nm [6, 7].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [7]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“NK105 exhibited 23% of drug loading with a hydrodynamic size of approx. 90 nm [7].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [7]
The cited source says what the claim attributes to it.
In the citing paper
“NK105 is composed of paclitaxel and modified mPEG-b-P(Asp) block copolymer (mPEG = 12,000 g/mol and P(Asp) = 8,000 g/mol) where half of the carboxylic groups P(Asp) block is modified with hydrophobic 4-phenyl-1-butanol to increase its hydrophobicity and improve drug incorporation [7].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [7]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Self-citationTumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 1×
“Passive targeting is based on the so-called enhanced permeability and retention (EPR) effect (Matsumura and Maeda, 1986; Maeda et al, 2000).”
BackgroundSelf-citationRowinsky, E. K., & Donehower, R. C. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321507 · Cited by 1,924
Hypersensitivity reactions from taxol.
Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Van Echo, D. A., Von Hoff, D. D., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174
Micellar Nanocontainers Distribute to Defined Cytoplasmic Organelles
Savić, R., Luo, L., Eisenberg, A., & Maysinger, D. (2003) · Science · doi:10.1126/science.1078192 · Cited by 1,113
Barriers to Drug Delivery in Solid Tumors
Jain, R. K. (1994) · Scientific American · doi:10.1038/scientificamerican0794-58 · Cited by 1,069
Block copolymer micelles as vehicles for drug delivery
Kazunori, K., Glenn S., K., Masayuki, Y., Teruo, O., & Yasuhisa, S. (1993) · Journal of Controlled Release · doi:10.1016/0168-3659(93)90172-2 · Cited by 877
Self-citationKim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821
Ibrahim, N. K., Desai, N. P., Legha, S. S., Soon‐Shiong, P., Theriault, R. L., Rivera, E., Esmaeli, B., Ring, S. E., Bedikian, A. Y., Hortobágyi, G. N., et al. (2002) · PubMed · Cited by 705
Development of the polymer micelle carrier system for doxorubicin
Nakanishi, T., Fukushima, S., Okamoto, K., Suzuki, M., Matsumura, Y., Yokoyama, M., Okano, T., Sakurai, Y., & Kataoka, K. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00341-8 · Cited by 570
Self-citation
Research works printed but not linked: 1
- 2. Hamaguchi T, Matsumura Y, Shirao Y, Shimada Y, Yamada Y, Muro Y, Okusaka T, Ueno H, Ikeda M, Watanabe N (2003) Phase I study of novel drug delivery system, NK911, a polymer micelle encapsulated doxor- ubicin. Proc Am Soc Clin Oncol 22: 571
Cited by
Items 101–200 of 565
Wang, Y.-C., Tang, L.-Y., Sun, T.-M., Li, C.-H., Xiong, M.-H., & Wang, J. (2008) · Biomacromolecules · doi:10.1021/bm700732g · Cited by 159
Combined cancer therapy by micellar-encapsulated drug and ultrasound
Rapoport, N. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2003.09.048 · Cited by 159
Xu, H., Yao, Q., Cai, C., Gou, J., Zhang, Y., Zhong, H., & Tang, X. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.012 · Cited by 158
Recent Advances in Nanomicelles Delivery Systems.
Tawfik, S. M., Azizov, S., Elmasry, M. R., Sharipov, M., & Lee, Y.-I. (2020) · Nanomaterials · doi:10.3390/nano11010070 · Cited by 156
Sustained Drug Release from Smart Nanoparticles in Cancer Therapy: A Comprehensive Review
Bai, X., Smith, Z., Wang, Y., Butterworth, S., & Tirella, A. (2022) · Micromachines · doi:10.3390/mi13101623 · Cited by 200
Novel extraction, rapid assessment and bioavailability improvement of quercetin: A review
Manzoor, M. F., Hussain, A., Sameen, A., Sahar, A., Khan, S., Siddique, R., Aadil, R. M., & Xu, B. (2021) · Ultrasonics Sonochemistry · doi:10.1016/j.ultsonch.2021.105686 · Cited by 173
Doxorubicin and paclitaxel loaded microbubbles for ultrasound triggered drug delivery
Cochran, M. C., Eisenbrey, J., Ouma, R. O., Soulen, M., & Wheatley, M. A. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.05.030 · Cited by 152
Polymer-Based Nanomaterials for Drug-Delivery Carriers
Yadav, H. K. S., Almokdad, A. A., shaluf, S. I. M., & Debe, M. S. (2019) · Nanocarriers for Drug Delivery · doi:10.1016/b978-0-12-814033-8.00017-5 · Cited by 148
Nanomedicines for the treatment of hematological malignancies
Deshantri, A. K., Varela-Moreira, A., Ecker, V., Mandhane, S. N., Schiffelers, R. M., Buchner, M., & Fens, M. H. A. M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.034 · Cited by 161
Ke, X., Ng, V. W. L., Ono, R. J., Chan, J. M. W., Krishnamurthy, S., Wang, Y., Hedrick, J. L., & Yang, Y. Y. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.061 · Cited by 146
“also developed PTX-loaded polymeric micelles (denoted as NK105) for PTX delivery [38].”
Application of Magnetic Nanoparticles to Gene Delivery
Kami, D., Takeda, S., Itakura, Y., Gojo, S., Watanabe, M., & Toyoda, M. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12063705 · Cited by 144
Zhai, J., Luwor, R. B., Ahmed, N., Escalona, R. M., Tan, F. H., Fong, C., Ratcliffe, J., Scoble, J. A., Drummond, C. J., & Tran, N. L. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b08125 · Cited by 151
Journal of Global Trends in Pharmaceutical Sciences
Rao, A., Korim, R., Reddy, D. S., & Mujavar, E. (2014) · Cited by 142
Shiraishi, K., Hamano, M., Ma, H., Kawano, K., Maitani, Y., Aoshi, T., Ishii, K. J., & Yokoyama, M. (2013) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.11.016 · Cited by 141
Self-citationPEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy
Yoshizawa, Y., Kono, Y., Ogawara, K., Kimura, T., & Higaki, K. (2011) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2011.04.008 · Cited by 148
McDaniel, J. R., Bhattacharyya, J., Vargo, K. B., Hassouneh, W., Hammer, D. A., & Chilkoti, A. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201200899 · Cited by 150
Alvarez‐Lorenzo, C., Sosnik, A., & Concheiro, Á. (2011) · Current Drug Targets · doi:10.2174/138945011795906615 · Cited by 155
Building nanostructures with drugs
Ma, W., Cheetham, A. G., & Cui, H. (2016) · Nano Today · doi:10.1016/j.nantod.2015.11.003 · Cited by 146
Fujiwara, Y., Mukai, H., Saeki, T., Ro, J., Lin, Y.-C., Nagai, S. E., Lee, K. S., Watanabe, J., Ohtani, S., Kim, S. B., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0391-z · Cited by 147
Progress in Polymeric Nano-Medicines for Theranostic Cancer Treatment
Ali, I., Alsehli, M., Scotti, L., Tullius Scotti, M., Tsai, S.-T., Yu, R.-S., Hsieh, M. F., & Chen, J.-C. (2020) · Polymers · doi:10.3390/polym12030598 · Cited by 134
Dhand, C., Prabhakaran, M. P., Beuerman, R. W., Lakshminarayanan, R., Dwivedi, N., & Ramakrishna, S. (2014) · RSC Advances · doi:10.1039/c4ra02861a · Cited by 146
Khalid, M. N., Simard, P., Hoarau, D., Dragomir, A., & Leroux, J. (2006) · Pharmaceutical Research · doi:10.1007/s11095-006-9662-5 · Cited by 157
Yokoyama, M. (2011) · Journal of Experimental & Clinical Medicine · doi:10.1016/j.jecm.2011.06.002 · Cited by 152
Self-citationAnsell, S. M., Johnstone, S. A., Tardi, P. G., Lo, L., Xie, S., Shu, Y., Harasym, T. O., Harasym, N. L., Williams, L. A., Bermudes, D. G., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800002y · Cited by 140
Clinical applications of nanomedicine in cancer therapy
Norouzi, M., Amerian, M., Amerian, M., & Atyabi, F. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.017 · Cited by 130
Paclitaxel-loaded PCL–TPGS nanoparticles: In vitro and in vivo performance compared with Abraxane®
Bernabeu, E., Helguera, G. F., Legaspi, M. J., González, L., Höcht, C., Taira, C. A., & Chiappetta, D. A. (2013) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2013.07.036 · Cited by 134
Paclitaxel dimers assembling nanomedicines for treatment of cervix carcinoma
Pei, Q., Hu, X., Liu, S., Li, Y., Xie, Z., & Jing, X. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.03.391 · Cited by 128
Sousa‐Pimenta, M., Estevinho, L. M., Szopa, A., Basit, M., Khan, K., Armaghan, M., Ibrayeva, M., Gürer, E. S., Călina, D. C., Hano, C., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1157306 · Cited by 134
Self-Assembled Poly(butadiene)-b-poly(ethylene oxide) Polymersomes as Paclitaxel Carriers
Li, S., Byrne, B., Welsh, J., & Palmer, A. F. (2006) · Biotechnology Progress · doi:10.1021/bp060208 · Cited by 150
Polyether based amphiphiles for delivery of active components
Gupta, S., Tyagi, R., Parmar, V. S., Sharma, S. K., & Haag, R. (2012) · Polymer · doi:10.1016/j.polymer.2012.04.047 · Cited by 133
Polymeric Micellar Delivery Systems in Oncology
Matsumura, Y. (2008) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyn116 · Cited by 121
Self-citationAdvances and applications of nanoparticles in cancer therapy
Huang, X., He, T., Liang, X., Xiang, Z., Liu, C., Zhou, S., Luo, R., Bai, L., Kou, X., Li, X., et al. (2024) · MedComm – Oncology · doi:10.1002/mog2.67 · Cited by 156
Nederberg, F., Appel, E., Tan, J. P. K., Kim, S. H., Fukushima, K., Sly, J., Miller, R. D., Waymouth, R. M., Yang, Y. Y., & Hedrick, J. L. (2009) · Biomacromolecules · doi:10.1021/bm900056g · Cited by 117
Yang, L., Wu, X., Liu, F., Duan, Y., & Li, S. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9949-4 · Cited by 135
Amphiphilic block co-polymers: Preparation and application in nanodrug and gene delivery
Xiong, X.-B., Binkhathlan, Z., Molavi, O., & Lavasanifar, A. (2012) · Acta Biomaterialia · doi:10.1016/j.actbio.2012.03.006 · Cited by 125
Multifunctional nanoparticles for use in theranostic applications
Cole, J. T., & Holland, N. B. (2015) · Drug Delivery and Translational Research · doi:10.1007/s13346-015-0218-2 · Cited by 123
Bioreducible core-crosslinked hyaluronic acid micelle for targeted cancer therapy
Han, H. S., Choi, K. Y., Ko, H., Jeon, J., Saravanakumar, G., Suh, Y. D., Lee, D. S., & Park, J. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.12.032 · Cited by 110
An overview of polymeric nanomicelles in clinical trials and on the market
Zheng, X., Xie, J., Zhang, X., Sun, W., Zhao, H., Li, Y., & Wang, C. (2020) · Chinese Chemical Letters · doi:10.1016/j.cclet.2020.11.029 · Cited by 114
Challenges facing colloidal delivery systems: From synthesis to the clinic
Johnston, A. P. R., Such, G. K., Ng, S. L., & Caruso, F. (2010) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2010.11.003 · Cited by 124
Yen, H.-C., Cabral, H., Mi, P., Toh, K., Matsumoto, Y., Liu, X., Koori, H., Kim, A., Miyazaki, K., Miura, Y., et al. (2014) · ACS Nano · doi:10.1021/nn504836s · Cited by 104
Self-citationStabilized micelles as delivery vehicles for paclitaxel
Yoncheva, K., Calleja, P., Agüeros, M., Petrov, P. D., Miladinova, I., Tsvetanov, C. B., & Irache, J. M. (2012) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2012.06.030 · Cited by 112
Translating materials design to the clinic
Hubbell, J. A., & Langer, R. (2013) · Nature Materials · doi:10.1038/nmat3788 · Cited by 112
Driving forces for drug loading in drug carriers
Li, Y., & Li, Y. (2015) · Journal of Microencapsulation · doi:10.3109/02652048.2015.1010459 · Cited by 109
Current State of the Art of New Tubulin Inhibitors in the Clinic
Kuppens, I. E. L. M. (2006) · Current Clinical Pharmacology · doi:10.2174/157488406775268200 · Cited by 108
Qu, G., Yao, Z., Zhang, C., Wu, X., & Ping, Q. (2009) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2009.01.004 · Cited by 106
Soluplus® micelles as a potential drug delivery system for reversal of resistant tumor
Jin, X., Zhou, B., Xue, L., & San, W. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.12.028 · Cited by 109
Nanoparticles for Targeted and Temporally Controlled Drug Delivery
Swami, A., Shi, J., Gadde, S., Votruba, A. R., Kolishetti, N., & Farokhzad, O. C. (2012) · Nanostructure science and technology · doi:10.1007/978-1-4614-2305-8_2 · Cited by 133
Recent Advances in Nanoparticle-Based Cancer Treatment: A Review
Bajpai, S., Tiwary, S. K., Sonker, M., Joshi, A., Gupta, V., Kumar, Y., Shreyash, N., & Biswas, S. (2021) · ACS Applied Nano Materials · doi:10.1021/acsanm.1c00779 · Cited by 105
He, Z., Schulz, A., Wan, X., Seitz, J., Bludau, H., Alakhova, D. Y., Darr, D. B., Perou, C. M., Jordan, R., Ojima, I., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.024 · Cited by 99
Harshita, Barkat, M. A., Beg, S., Pottoo, F. H., & Ahmad, F. J. (2019) · Nanomedicine · doi:10.2217/nnm-2018-0313 · Cited by 102
A Pharmacokinetic Overview of Nanotechnology-Based Drug Delivery Systems: An ADME-Oriented Approach
Hamidi, M., Azadi, A., Rafiei, P., & Ashrafi, H. (2013) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2013007419 · Cited by 108
Ernsting, M. J., Murakami, M., Undzys, E., Aman, A. M., Press, B., & Li, S. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.07.043 · Cited by 104
Lv, P., Wei, W., Yue, H., Yang, T., Wang, L.-Y., & Ma, G. (2011) · Biomacromolecules · doi:10.1021/bm2010774 · Cited by 97
Exploring the Application of Micellar Drug Delivery Systems in Cancer Nanomedicine
Wang, Q., Atluri, K., Tiwari, A. K., & Babu, R. J. (2023) · Pharmaceuticals · doi:10.3390/ph16030433 · Cited by 113
Lee, H., Zeng, F., Dunne, M., & Allen, C. (2005) · Biomacromolecules · doi:10.1021/bm050451h · Cited by 95
Recent advances in intravenous delivery of poorly water-soluble compounds
Shi, Y., Porter, W., Merdan, T., & Li, L. C. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903307423 · Cited by 102
Ernsting, M. J., Tang, W.-L., MacCallum, N., & Li, S. (2011) · Bioconjugate Chemistry · doi:10.1021/bc200284b · Cited by 105
Khalifa, A. M., Elsheikh, M. A., Khalifa, A., & Elnaggar, Y. S. R. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.08.034 · Cited by 103
Impact of nanotechnology in cancer: emphasis on nanochemoprevention
Mukhtar, H. (2012) · International Journal of Nanomedicine · doi:10.2147/ijn.s26026 · Cited by 103
Micellar carriers for the delivery of multiple therapeutic agents
Thipparaboina, R., Chavan, R. B., Kumar, D. K., Modugula, S., & Shastri, N. R. (2015) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2015.07.046 · Cited by 97
Polymeric micelle nanocarriers in cancer research
Shin, D. H., Tam, Y. T., & Kwon, G. S. (2016) · Frontiers of Chemical Science and Engineering · doi:10.1007/s11705-016-1582-2 · Cited by 99
Negishi, T., Koizumi, F., Uchino, H., Kuroda, J., Kawaguchi, T., Naito, S., & Matsumura, Y. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603311 · Cited by 92
Self-citationOvercoming the road blocks: advancement of block copolymer micelles for cancer therapy in the clinic
Houdaihed, L., Evans, J. C., & Allen, C. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00188 · Cited by 91
Polymeric micelles with stimuli-triggering systems for advanced cancer drug targeting
Nakayama, M., Akimoto, J., & Okano, T. (2014) · Journal of drug targeting · doi:10.3109/1061186x.2014.936872 · Cited by 98
Molavi, O., Ma, Z., Mahmud, A., Alshamsan, A., Samuel, J., Lai, R. L., Kwon, G. S., & Lavasanifar, A. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2007.06.032 · Cited by 97
Letchford, K., Liggins, R., Wasan, K. M., & Burt, H. M. (2008) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2008.08.003 · Cited by 100
Polypeptide-based drug delivery systems for programmed release
Wang, X., Song, Z., Wei, S., Ji, G., Zheng, X., Fu, Z., & Cheng, J. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120913 · Cited by 92
Zhao, X., Poon, Z., Engler, A. C., Bonner, D. K., & Hammond, P. T. (2012) · Biomacromolecules · doi:10.1021/bm201873u · Cited by 88
Reddy, L. H., & Bazile, D. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.10.007 · Cited by 98
Zhang, J., Ellsworth, K., & Ma, P. X. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.019 · Cited by 91
Emami, J., Rezazadeh, M., Varshosaz, J., Tabbakhian, M., & Aslani, A. (2012) · Journal of Nanomaterials · doi:10.1155/2012/358782 · Cited by 99
Factors affecting toxicity and efficacy of polymeric nanomedicines
Igarashi, E. (2008) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2008.02.007 · Cited by 100
Wang, G., Yu, B., Wu, Y., Huang, B., Yuan, Y., & Liu, C. S. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.02.004 · Cited by 90
A polymeric micelle MRI contrast agent with changeable relaxivity
Nakamura, E., Makino, K., Okano, T., Yamamoto, T., & Yokoyama, M. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.05.030 · Cited by 85
Self-citationKim, Y., Pourgholami, M. H., Morris, D. L., & Stenzel, M. H. (2012) · Biomacromolecules · doi:10.1021/bm201730p · Cited by 94
Elsabahy, M., Perron, M.-È., Bertrand, N., Yu, G.-E., & Leroux, J.-C. (2007) · Biomacromolecules · doi:10.1021/bm070226v · Cited by 83
RetractedHoang, B., Lee, H., Reilly, R. M., & Allen, C. (2009) · Molecular Pharmaceutics · doi:10.1021/mp8002418 · Cited by 83
Multi-targeting cancer chemotherapy using temperature-responsive drug carrier systems
Nakayama, M., & Okano, T. (2010) · Reactive and Functional Polymers · doi:10.1016/j.reactfunctpolym.2010.08.006 · Cited by 86
Ultrasound-mediated micellar drug delivery
Rapoport, N. Y. (2012) · International Journal of Hyperthermia · doi:10.3109/02656736.2012.665567 · Cited by 89
The Drug Discovery by NanoMedicine and its Clinical Experience
Matsumura, Y. (2014) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyu046 · Cited by 80
Self-citationTargeted Delivery System of Nanobiomaterials in Anticancer Therapy: From Cells to Clinics
Jin, S., Jin, H., & Hong, S. (2014) · BioMed Research International · doi:10.1155/2014/814208 · Cited by 95
Chemical Approaches to Synthetic Drug Delivery Systems for Systemic Applications
Braatz, D., Cherri, M., Tully, M., Dimde, M., Ma, G., Mohammadifar, E., Reisbeck, F., Ahmadi, V., Schirner, M., & Haag, R. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202203942 · Cited by 80
Disposition of Drugs in Block Copolymer Micelle Delivery Systems: From Discovery to Recovery
Aliabadi, H. M., Shahin, M., Brocks, D. R., & Lavasanifar, A. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847100-00001 · Cited by 84
From Composition to Cure: A Systems Engineering Approach to Anticancer Drug Carriers
MacEwan, S. R., & Chilkoti, A. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201610819 · Cited by 79
Clinical developments of antitumor polymer therapeutics
Parveen, S., Arjmand, F., & Tabassum, S. (2019) · RSC Advances · doi:10.1039/c9ra04358f · Cited by 84
Rezaei, A., Rafieian, F., Akbari‐Alavijeh, S., Kharazmi, M. S., & Jafari, S. M. (2022) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2022.102728 · Cited by 84
Ma, P., Wang, G., Men, K., Li, C., Gao, N., & Li, L. (2024) · Nano TransMed · doi:10.1016/j.ntm.2024.100036 · Cited by 78
What nanomedicine in the clinic right now really forms nanoparticles?
Svenson, S. (2014) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1257 · Cited by 88
Gaowa, A., Horibe, T., Kohno, M., Sato, K., Harada, H., Hiraoka, M., Tabata, Y., & Kawakami, K. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2013.12.021 · Cited by 77
Micellization of cisplatin (NC-6004) reduces its ototoxicity in guinea pigs
Baba, M., Matsumoto, Y., Kashio, A., Cabral, H., Nishiyama, N., Kataoka, K., & Yamasoba, T. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.07.026 · Cited by 79
Self-citationBioavailability of Herbal Products
Mukherjee, P. K., Harwansh, R. K., & Bhattacharyya, S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800874-4.00010-6 · Cited by 102
Sakai-Kato, K., Nishiyama, N., Kozaki, M., Nakanishi, T., Matsuda, Y., Hirano, M., Hanada, H., Hisada, S., Onodera, H., Harashima, H., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.05.259 · Cited by 75
Self-citationUdaya Rajesh, R., & Sangeetha, D. (2023) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2023.104881 · Cited by 88
Leite, M. L., da Cunha, N. B., & Costa, F. F. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.010 · Cited by 76
Polyamide/Poly(Amino Acid) Polymers for Drug Delivery
Boddu, S. H. S., Bhagav, P., Karla, P. K., Jacob, S., Adatiya, M. D., Dhameliya, T. M., Ranch, K. M., & Tiwari, A. K. (2021) · Journal of Functional Biomaterials · doi:10.3390/jfb12040058 · Cited by 83
Polypeptides and polyaminoacids in drug delivery
González-Aramúndiz, J. V., Lozano, M. V., Sousa‐Herves, A., Fernández-Megía, E., & Csaba, N. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.647906 · Cited by 81
van (2010) · International Journal of Nanomedicine · doi:10.2147/ijn.s13482 · Cited by 79
Behroozi, F., Abdkhodaie, M.-J., Abandansari, H. S., Satarian, L., Molazem, M., Al‐Jamal, K. T., & Baharvand, H. (2018) · Acta Biomaterialia · doi:10.1016/j.actbio.2018.05.031 · Cited by 73
Kim, Y., Binauld, S., & Stenzel, M. H. (2012) · Biomacromolecules · doi:10.1021/bm301351e · Cited by 82
Li, W., Nakayama, M., Akimoto, J., & Okano, T. (2011) · Polymer · doi:10.1016/j.polymer.2011.06.026 · Cited by 76
Metadata
- Authors
- Hamaguchi, T., Matsumura, Y., Suzuki, M., Shimizu, K., Goda, R., Nakamura, I., Nakatomi, I., Yokoyama, M., Kataoka, K., & Kakizoe, T.
- Affiliations
- National Cancer Centre Japan (JP)
- Nippon Kayaku (Japan) (JP)
- NanoCarrier (Japan) (JP)
- Kanagawa Academy of Science and Technology (JP)
- The University of Tokyo (JP)
- Corresponding author
- Matsumura, Y
- Venue
- British Journal of Cancer
- Published
- 2005-03-22
- Volume
- 92
- Issue
- 7
- Pages
- 1240-1246
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- PMC
- PMC2361981
- OpenAlex
- W2112927879
- Cited by
- 565
- References
- 23
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 18 · 2023: 18 · 2022: 23 · 2021: 23 · 2020: 29 · 2019: 21 · 2018: 27 · 2017: 36 · 2016: 41 · 2015: 50 · 2014: 40 · 2013: 29 · 2012: 33
- FWCI
- 10.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- www.springer.com/tdm (unspecified)
- Locations
- British Journal of Cancer (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- paclitaxel, micellar nanoparticles, nanoparticle drug delivery, neurotoxicity, antitumour activity, pharmacokinetics, pharmacodynamics, block copolymer micelles, colorectal cancer, HT-29 xenograft, drug leakage, sustained drug release, metastatic solid tumors
- MeSH terms
- Animals, Antineoplastic Agents, Phytogenic, Chemistry, Pharmaceutical, Colonic Neoplasms, Humans, Nervous System, Transplantation, Heterologous, Paclitaxel, Area Under Curve, Nanostructures, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.